HEP或EP方案治疗肺及肺外小细胞癌的临床观察
Chinese Journal of Cancer Prevention and Treatment(2008)
Abstract
目的:评价HEP或EP方案治疗肺及肺外小细胞癌的有效性和安全性。方法:对60例小细胞癌患者分别采用HEP方案(38例)和EP方案(22例)治疗。HEP方案为羟基喜树碱(HCPT)6mg/m2,静脉滴入,d1~d5;依托泊苷(Vp-16)0.1g,静脉滴入,d1~d4或d5,或Vp-16软胶囊50mg,口服,d1~d10或d14,或替尼泊苷(Vm-26 0.1g,静脉滴入,d1~d4或d5;DDP 20mg,静脉滴入,d1~d5。28d重复。EP方案除不用HCPT外,其余用药同上。结果:HEP组可评价疗效37例,RR为62.2%,EP组RR为50.0%,P=0.361。HEP方案对初治小细胞癌有效率达79.2%,对肺小细胞癌的客观疗效为71.0%,但与EP组比较差异均无统计学意义,P值分别为0.063和0.344。两组的中位TTP和中位OS差异也无统计学意义,P值分别为0.386和0.660。其主要毒副反应均为骨髓抑制。结论:HEP方案对多种小细胞癌具有较好的疗效,毒性可以耐受,值得进一步研究。
MoreTranslated text
Key words
Carcinoma,Combimation,Drug therapy,Lung neoplasms/drug therapy,Smail cell/drug therapy
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined